Cypher Genomics, headquartered in San Diego, focuses on the interpretation and analysis of DNA sequence information for research, clinical, individual disease risk assessment, and forensic purposes. Cypher leverages both a suite of proprietary computational tools to interrogate the molecular effects of sequence variation as well as sophisticated methodology for consolidating disease risk and phenotype information for individual genomic health profile reporting.
Nicholas J. Schork, Ph.D., founder and CEO of Cypher Genomics, said, “As is documented and well-known, all modern diagnostic and clinical tests and resources have their limitations, and this is no less true for those based on contemporary genetic and wireless technologies. However, the integration and scientifically-backed use of a variety of state-of-the-field tests and resources should be taken seriously if for no other reason than to determine what it makes sense to retain in optimizing individual healthcare.
“In this context, I personally am excited by what we will learn from our early experiences so that we can improve and refine things going forward. In fact, I am hoping to be a DNA 3-Day client myself and witness it first-hand,” added Dr. Schork, a quantitative biomedical researcher at the Scripps Translational Science Institute of Scripps Health and The Scripps Research Institute.
For more information: cyphergenomics.com